TY - JOUR
T1 - Treatment experience with a novel 30-mm hydrostatic balloon in esophageal dysmotility
T2 - a multicenter retrospective analysis
AU - Sloan, Joshua A.
AU - Triggs, Joseph R.
AU - Pandolfino, John E.
AU - Dbouk, Mohamad
AU - Brewer Gutierrez, Olaya I.
AU - El Zein, Mohamad
AU - Quader, Farhan
AU - Ichkhanian, Yervant
AU - Gyawali, C. Prakash
AU - Rubenstein, Joel H.
AU - Khashab, Mouen A.
N1 - Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: J. E. Pandolfino: Ownership interest in Crospon and Medtronic; consultant for Medtronic, Sandhill Scientific, and Torax; speaker for Astra Zeneca; scientific consultant for Ironwood and Diversatek; legal consultant for Takeda, grant recipient from Impleo. C. P. Gyawali: Consultant for Medtronic, Diversatek, Ironwood, Quintiles, and Isothrive. M. A. Khashab: Consultant for BSCI, Medtronic, and Olympus. All other authors disclosed no financial relationships.
Publisher Copyright:
© 2020 American Society for Gastrointestinal Endoscopy
PY - 2020/12
Y1 - 2020/12
N2 - Background and Aims: The newest addition in the management of achalasia and esophagogastric junction outflow obstruction (EGJOO) is a 30-mm hydrostatic balloon dilator that uses impedance planimetry technology. It allows for the measurement of the diameter and cross-sectional area to determine effective dilation. We aimed to (1) determine the clinical success (defined as a decrease in Eckardt score to ≤3) in the treatment of esophageal motility disorders and (2) report the safety (rate/severity of adverse events). Methods: This retrospective multicenter study involved 4 centers. Patients with esophageal motility disorders who underwent hydrostatic balloon dilation between January 2015 and October 2018 were included. Results: Fifty-one patients (mean age, 54.1 years; women, 49%) underwent hydrostatic dilation for achalasia (n = 37) or EGJOO (n = 14) during the study period. Forty-seven patients had a median baseline Eckardt score of 5 (range, 3-8; achalasia, n = 35, 6 [range, 3-8]; EGJOO, n = 12, 4 [range, 3.25-6.5]). Clinical success was achieved in 60% of cases (achalasia vs EGJOO: 68.4% vs 33.3%, P = .18). Dilation resulted in a significant decrease in the median Eckardt score from 5 (range, 3-8) to 1.5 (range, 1-4.75; P < .001). Patients with achalasia had a decrease in Eckardt score from 6 (range, 3-8) to 1 (range, 1-4; P < .001), whereas those with EGJOO experienced no significant change. One patient had mild postprocedure chest pain. Conclusions: The hydrostatic balloon dilator is a new tool in our armamentarium to treat esophageal motility disorders. This is the first multicenter study showing the device to be safe and moderately efficacious.
AB - Background and Aims: The newest addition in the management of achalasia and esophagogastric junction outflow obstruction (EGJOO) is a 30-mm hydrostatic balloon dilator that uses impedance planimetry technology. It allows for the measurement of the diameter and cross-sectional area to determine effective dilation. We aimed to (1) determine the clinical success (defined as a decrease in Eckardt score to ≤3) in the treatment of esophageal motility disorders and (2) report the safety (rate/severity of adverse events). Methods: This retrospective multicenter study involved 4 centers. Patients with esophageal motility disorders who underwent hydrostatic balloon dilation between January 2015 and October 2018 were included. Results: Fifty-one patients (mean age, 54.1 years; women, 49%) underwent hydrostatic dilation for achalasia (n = 37) or EGJOO (n = 14) during the study period. Forty-seven patients had a median baseline Eckardt score of 5 (range, 3-8; achalasia, n = 35, 6 [range, 3-8]; EGJOO, n = 12, 4 [range, 3.25-6.5]). Clinical success was achieved in 60% of cases (achalasia vs EGJOO: 68.4% vs 33.3%, P = .18). Dilation resulted in a significant decrease in the median Eckardt score from 5 (range, 3-8) to 1.5 (range, 1-4.75; P < .001). Patients with achalasia had a decrease in Eckardt score from 6 (range, 3-8) to 1 (range, 1-4; P < .001), whereas those with EGJOO experienced no significant change. One patient had mild postprocedure chest pain. Conclusions: The hydrostatic balloon dilator is a new tool in our armamentarium to treat esophageal motility disorders. This is the first multicenter study showing the device to be safe and moderately efficacious.
UR - http://www.scopus.com/inward/record.url?scp=85089250514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089250514&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2020.04.076
DO - 10.1016/j.gie.2020.04.076
M3 - Article
C2 - 32417296
AN - SCOPUS:85089250514
SN - 0016-5107
VL - 92
SP - 1251
EP - 1257
JO - Gastrointestinal endoscopy
JF - Gastrointestinal endoscopy
IS - 6
ER -